Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Citius Pharmaceuticals Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $28.62 (market cap $157.51B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 8409.5× Citius Pharmaceuticals Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 3.8% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BBVA | CTXR | |
|---|---|---|
Market Cap | $157.51B | $18.73M |
Sector | Financials | Health |
52-Week High | $28.36 | $1.82 |
52-Week Low | $17.96 | $0.48 |
Dividend Yield | 3.8% | — |
Enterprise Value | — | $14.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $28.35, up 0.75% today, with a bullish technical signal from moving averages and strong fundamental performance. The bank reported Q2 2026 net profit growth of 11.4% year-over-year, driven by Mexico operations, and announced a $2.3 billion buyback. Revenue reached $39.42 billion in 2025, with net income margin at 26.13% and ROE of 18.5%, though cash flow was negative in 2024.
Outlook is positive with raised profitability guidance (ROTE ~21%) and analyst consensus leaning buy (54%), but risks include a Spanish court trial for spying allegations and antitrust probes. The stock offers value with a P/E of 12.98, yet investors should monitor legal overhangs and macroeconomic volatility in core markets like Spain and Mexico.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
